- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01938560
REMS Retigabine Study
REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention With POTIGA™
As part of a post-marketing commitment, GSK will conduct a survey of prescribers' and pharmacists' understanding of the risk of urinary retention with retigabine products. This is to address the effectiveness of the Risk Evaluation and Mitigation Strategy (REMS) as outlined in the REMS approved by the FDA on 10th June 2011. The objectives of this survey are to assess prescribers' and pharmacists' understanding of the risk of urinary retention and the symptoms of acute urinary retention potentially associated with retigabine use as evaluated by a survey instrument.
This is a cross-sectional study of approximately 200 physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months, and 200 pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months. The primary outcome of the survey is the proportion of physicians and pharmacists providing correct responses to a series of questions concerning the risk of urinary retention and the symptoms of acute urinary retention that may be associated with retigabine. The risks captured will be those described in the retigabine Dear Healthcare Provider (DHCP) letters, specifically risks of urinary retention.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Able to read, speak, and understand English.
- Willing to take the online survey or have the survey administered via a telephone interview, including electronically signing a Confidentiality & Consent agreement and completing all study protocol-specified procedures.
- Prescribed retigabine within the past 12 months (prescribing physicians)
- Filled a prescription for at least one AED within the previous three months (pharmacists).
Exclusion Criteria:
- Physicians or pharmacists meeting any of the following criteria will not be eligible to take the survey:
- The physician or pharmacist is currently employed by, or is a representative of any of the following:
- A pharmaceutical company or manufacturer of medicines or healthcare products.
- Contributor/editor to published guideline committees for epilepsy or UR.
- The physician or pharmacist has a visual impairment that would prevent him or her from being able to read independently.
- The physician or pharmacist participated in the Pilot REMS study for retigabine.
- The physician or pharmacist is an employee of GSK or Concentrics Research.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Physicians
Retigabine Physicians (e.g.
neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
|
Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
|
Pharmacists
Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
|
Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of physicians and pharmacists providing correct responses to a series of questions concerning the risk of urinary retention and the symptoms of acute urinary retention that may be associated with retigabine.
Time Frame: 12 months
|
The outcome is a survey response by physicians and pharmacists so is not related to the drug exposure.
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116490
- WEUKBRE5993 (Other Identifier: GSK)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Survey Responses
-
Pennington Biomedical Research CenterWeight Watchers InternationalEnrolling by invitation
-
Kazan State Medical UniversityInterregional Clinical Diagnostic Center, RussiaCompletedPelvic Congestion SyndromeRussian Federation
-
University Hospital, AngersCompleted
-
FondationbHopaleNot yet recruitingStroke Rehabilitation | Postural EquilibriumFrance
-
New York Obesity and Nutrition Research CenterColumbia University; St. Luke's-Roosevelt Hospital CenterUnknown
-
Chestnut Health SystemsNational Institute of Mental Health (NIMH)Not yet recruitingChild Abuse | Mental Health | Implementation Science | Decision Making | Family | Child Welfare | Decision Making, Shared | Social Facilitation | Policy | Decision Support Technique | Organizations | Consensus
-
Istituto Auxologico ItalianoRecruiting
-
Hospices Civils de LyonWithdrawnLeukemia, Myeloid
-
SK Bioscience Co., Ltd.International Vaccine InstituteWithdrawn